5,211 reports of this reaction
4.8% of all TERIFLUNOMIDE reports
#2 most reported adverse reaction
MULTIPLE SCLEROSIS RELAPSE is the #2 most commonly reported adverse reaction for TERIFLUNOMIDE, manufactured by Genzyme Corporation. There are 5,211 FDA adverse event reports linking TERIFLUNOMIDE to MULTIPLE SCLEROSIS RELAPSE. This represents approximately 4.8% of all 108,080 adverse event reports for this drug.
TERIFLUNOMIDE has an overall safety score of 78 out of 100. Patients taking TERIFLUNOMIDE who experience multiple sclerosis relapse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS RELAPSE is moderately reported among TERIFLUNOMIDE users, representing a notable but not dominant share of adverse events.
In addition to multiple sclerosis relapse, the following adverse reactions have been reported for TERIFLUNOMIDE:
The following drugs have also been linked to multiple sclerosis relapse in FDA adverse event reports:
MULTIPLE SCLEROSIS RELAPSE has been reported as an adverse event in 5,211 FDA reports for TERIFLUNOMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS RELAPSE accounts for approximately 4.8% of all adverse event reports for TERIFLUNOMIDE, making it one of the most commonly reported side effect.
If you experience multiple sclerosis relapse while taking TERIFLUNOMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.